 |
|
|
|
 |
|
|
| Article 1 to 10 out of 15 concerning Affibody AB
|
-
Newly Discovered Protein Inhibits the Formation of the Precursor to Alzheimer's Plaques
(03/31/2008)
Unexpected Discovery Made by Swedish Researchers within the Field of Alzheimer
As of today, there is no cure or effective treatment of Alzheimer's disease. Swedish researchers have now through their discoveries opened up new possible strategies for potential treatment of the actual cause of the disease. These results have been ...
-
Affibody to start clinical development of a approach for the diagnosis of cancer
(09/28/2007)
Swedish MPA gives go ahead for the clinical trial of Affibody's molecular imaging agent designed to improve the diagnosis of HER2-positive breast cancer.
Affibody Holding AB has received a letter from the Swedish Medical Product Agency (MPA) allowing it to begin an exploratory clinical trial of a new approach for diagnosing an aggressive form of breast cancer. The approach, which is based on the ...
-
Affibody appoints Erik Walldén as CEO
(07/05/2007)
Affibody AB has appointed Erik Walldén as CEO and has elected two new members of the Board of Directors, Peter Buhl Jensen, MD, PhD and Gillies O'Bryan-Tear, MD. Erik Walldén will assume his new role on July 15. He has an extensive experience from ...
-
Affibody to publish data on therapeutic effects of Affibody molecules in a cancer model
(03/19/2007)
Affibody AB announced that a scientific article will occur in the March 15 issue of Cancer Research, describing the successful application of Affibody® molecules as targeted therapeutics. The potential therapeutic product is a fusion protein between ...
-
Affibody molecules for cancer imaging made by chemical synthesis
(03/06/2007)
Affibody AB announced that Cancer Research, the official publication of American Association of Cancer Research (AACR), has published an article demonstrating excellent visualization of HER2-expressing tumors using a chemically produced Affibody® ...
-
Affibody has obtained a granted patent on the Microbead display technology
(02/16/2007)
Affibody AB announced that the European patent office has granted a patent application regarding a Microbead-based system to be used for rapid selection of Affibody® molecules and other small binding proteins. Last year the US patent office granted ...
-
Algeta and Affibody Initiate Anticancer Targeted Therapy Collaboration
(08/18/2006)
Algeta ASA and Affibody AB announced a research collaboration agreement to develop novel targeted radiotherapeutics. The collaboration will combine Algeta's TH-1 technology for attaching the alpha-particle emitting radionuclide thorium-227 to ...
-
Affibody AB and GE Healthcare Enter a Research Agreement
(06/21/2006)
Affibody AB has entered a research agreement with GE Healthcare, a division of the General Electric Company. Under the agreement, Affibody will provide Affibody® molecules for three disease targets as defined by GE Healthcare.Affibody® molecules, ...
-
Affibody AB appoints Dr. Ulf Boberg as Chief Executive Officer
(06/07/2006)
Affibody AB announced that Dr. Ulf Boberg has been appointed Chief Executive Officer as from June 1, 2006.Dr. Ulf Boberg, who joined Affibody in January 2006 as Senior Vice President Development, replaces Dr. Carl-Johan Dalsgaard who as been acting ...
-
Affibody AB provides novel molecular imaging agents for visualizing HER2-expressing cancer
(05/09/2006)
Affibody AB announced that Cancer Research, the official publication of American Association of Cancer Research (AACR), has published an article by Affibody and collaborators on the development and evaluation of a new targeting molecule that can be ...
Additional information
Affibody AB
Bromma, Sweden
Company
|
|
|
|
|
|
Top
